Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL
Condition(s):CD22+ Relapsed/Refractory B-ALLLast Updated:January 19, 2017Withdrawn
Hide Studies Not Open or Pending
Condition(s):CD22+ Relapsed/Refractory B-ALLLast Updated:January 19, 2017Withdrawn
Condition(s):Systemic Lupus ErythematosusLast Updated:May 6, 2016Completed
Condition(s):Systemic Lupus ErythematosusLast Updated:May 12, 2015Completed
Condition(s):Systemic Lupus ErythematosusLast Updated:July 12, 2012Completed
Condition(s):Systemic Lupus ErythematosusLast Updated:February 12, 2014Completed
Condition(s):Non Hodgkin’s Lymphoma; NHL; Aggressive NHL; Diffuse Large B-cell LymphomaLast Updated:August 18, 2021Withdrawn
Condition(s):Systemic Lupus ErythematosusLast Updated:October 3, 2018Completed
Condition(s):Systemic Lupus ErythematosusLast Updated:July 12, 2012Completed
Condition(s):Lupus Erythematosus, SystemicLast Updated:April 3, 2012Terminated
Condition(s):LymphomaLast Updated:July 6, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.